相关临床试验
3
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
尚未招募
1
33.3%
暂停
1
33.3%
撤回
1
33.3%
暂无批准数据
- Australia is preparing to launch the world's first clinical trial of PaedNeoVax (PTX-108), a personalized mRNA vaccine for children with aggressive brain tumors, though a start date has not yet been set. - The vaccine uses small samples of a patient's tumor to engage T cells to detect and attack cancer markers on tumor cell surfaces, with the trial led clinically by Professor Jordan Hansford of SAHMRI and the University of Adelaide. - The federal government has supported PTX-108 development with a $2.58 million Medical Research Future Fund grant, while the family of 16-year-old Coby Metzler, diagnosed with diffuse midline glioma, is seeking compassionate access outside the trial. - Experts emphasize that clinical trials are necessary to establish the safety blueprint needed to protect children from potential harm, even as advocates call for faster access to experimental treatments.
- A nationwide clinical trial is underway in Australia testing HB-1, a novel combination therapy for panic disorder that targets the body's central stress response system rather than neurotransmitters. - The treatment combines two existing TGA-approved medications and aims to reduce physical symptoms like elevated heart rate and shaking without the side effects or addiction risks of current therapies. - The trial involves 20 sites across Australia and is recruiting participants aged 18-65 with diagnosed panic disorder, offering hope for the estimated 5% of Australians affected by this debilitating condition. - No new medications have been approved for panic disorder since 2003, highlighting the urgent need for alternative treatment options as current therapies often prove ineffective or cause intolerable side effects.
